An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia

NCT01175135 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

259

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: PF-02545920
DRUG: PF-02545920
DRUG: Placebo
DRUG: Risperidone

Sponsor

Pfizer